Hyperhomocysteinemia, paraoxonase concentration and cardiovascular complications in Tunisian patients with nondiabetic renal disease

Clinical Biochemistry

Volumn 42, Issue 9, 2009, Pages 777-782

  Kerkeni, Mohsen ^a   Letaief, Ahmed ^b   Achour, Abdellatif ^b   Miled, Abdelhedi ^c   Trivin, Francois ^d   Maaroufi, Khira ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d UNIVERSITÉ DE TOURS   (France)

Author keywords

Cardiovascular complications; Chronic renal disease; Hyperhomocysteinemia; Paraoxonase concentration

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HOMOCYSTEINE; PHENYLACETIC ACID;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHEMOLUMINESCENCE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPECTROPHOTOMETRY; TUNISIA;

ADULT; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOIMMUNOASSAY; TRIGLYCERIDES; TUNISIA; VITAMIN B 12;

EID: 67349147867     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.02.009     Document Type: Article

References (61)

1. Abderrahim E., Zouaghi K., Hedri H., et al. Renal replacement therapy for diabetic end-stage renal disease. Experience of a Tunisian hospital centre. Diabetes Metab. 27 (2001) 584-590
2. Ben Maïz H., Abderrahim E., Ben Moussa F., Goucha R., and Karoui C. Epidemiology of glomerular diseases in Tunisian from 1975 to 2005. Influence of changes in healthcare and society. Bull. Acad. Natl. Med. 190 (2006) 403-416
3. Counil E., Cherni N., Hkarrat M., Achour A., and Trimech H. Trends of incidence dialysis patients in Tunisia between 1992 and 2001. Am. J. Kidney Dis. 51 (2008) 463-470
4. Anderson J.L., Muhlestein J.B., Horne B.D., et al. Plasma homocysteine predicts mortality independently of tradictional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 102 (2000) 1227-1232
5. Cavalca V., Cighetti G., Bamonti F., et al. Oxidative stress and homocysteine in coronary artery disease. Clin. Chem. 47 (2001) 887-892
6. Perry I.J. Homocysteine, hypertension and strok. J. Hum. Hypertens. 13 (1999) 289-293
7. Kerkeni M., Addad F., Chauffert M., et al. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin. Biochem. 39 (2006) 821-825
8. 12, folate, homocysteine, and creatinine in predicting outcomes in heart transplant recipients. Am. J. Cardiol. 89 (2002) 834-837
9. Mills J.L., Scott J.M., Kirke P.N., et al. homocysteine and neural tube defects. J. Nutr. 126 (1996) 756S-760S
10. Sachdev P.S., Valenzuela M., Wang X.L., Looi J.C., and Brodaty H. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 58 (2002) 1539-1541
11. Dennis V.W., and Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int. Suppl. 57 (1996) S11-S17
12. Ducloux D., Motte G., Challier B., Gibey R., and Chalopin J.M. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J. Am. Soc. Nephrol. 11 (2000) 134-137
13. Gupta A., and Robinson K. Hyperhomocysteinemia and end-stage renal disease. J. Nephrol. 10 (1997) 77-84
14. Guttormen A.B., Ueland P.M., Svarstad E., and Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int. 52 (1997) 495-502
15. Perna A.F., Ingrosso D., Satta E., Lombardi C., Acanfora F., and De Santo N.G. Homocysteine metabolism in renal failure. Curr. Opin. Clin. Nutr. Metab. Care 7 (2004) 53-57
16. Mackness M., Durrington P., and Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr. Opin. Lipidol. 15 (2004) 399-404
17. Jakubowski H., Zhang L., Bardeguez A., and Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ. Res. 87 (2000) 45-51
18. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolyse: a protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275 (2000) 3957-3962
19. Jakubowski H., Ambrosius W.T., and Pratt J.H. Genetic determinants of homocysteine thiolactone activity in humans: implication for atherosclerosis. FEBS Lett. 491 (2001) 35-39
20. Jakubowski H. Synthesis of homocysteine thiolactone in normal and malignant cells. In: Graham I., Refsum H., Rosenberg I.H., and Ueland P.M. (Eds). Homocysteine metabolism: from Basis science to clinical medicine (1997), Kluwer Academic Publishers, Dordrecht 157-165
21. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 13 (1999) 2277-2283
22. Jakubowski H. Homocysteine thiolactone and S-nitro-homocysteine mediate incorporation of homocysteine into protein in humans. Clin. Chem. Lab. Med. 41 (2003) 1462-1466
23. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell. Mol. Life Sci. 61 (2004) 470-487
24. Mercie P., Garmier O., Lascoste L., et al. Homocysteine thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features. Apoptosis 5 (2000) 403-411
25. Kerkeni M., Tnani M., Chuniaud L., et al. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a stronger proapoptotic and proinflammation homocysteine thiolactone. Mol. Cell. Biochem. 291 (2006) 119-126
26. Jakubowski H. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clin. Chem. Lab. Med. 43 (2005) 1011-1014
27. Jakubowski H. Pathophysiological consequences of homocysteine excess. J. Nutr. 136 (2006) 1741S-1749S
28. Jakubowski H. The molecular basis of homocysteine thiolactone mediated vascular disease. Clin. Chem. Lab. Med. 45 (2007) 1704-1716
29. Shishehbor M.H., Oliveira L.P., Lauer M.S., et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality in chronic kidney disease. Am. J. Cardiol. 101 (2008) 1741-1746
30. Yi F., and Li P.L. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am. J. Nephro. 28 (2008) 254-264
31. Suehiro T., Ikeda Y., Shiinoki T., et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J. Atheroscler. Thromb. 9 (2002) 133-138
32. Dronca M., Pasca S.P., Nemes B., Vlase L., and Vladutiu D. Serum paraoxonase 1 activities and Homocysteinemia in hemodialysis patients. Clin. Chem. Lab. Med. 46 (2008) 880-881
33. Kerkeni M., Added F., Ben Farhat M., et al. Hyperhomocysteinemia and parameters of antioxidative defence in Tunisian patients with coronary heart disease. Ann. Clin. Biochem. 45 (2008) 193-198
34. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Inter. Med. 130 (1999) 461-470
35. Vlagopoulos P.T., Tighiouart H., Weiner D.E., et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J. Am. Soc. Nephrol. 16 (2005) 3403-3410
36. World Health Organisation (WHO): Nutritional anaemias. Report of a WHO scientific group. World. Health Organisation Tech. Rep. Ser. 405 (1968) 5-37
37. Itahara T., Suehiro T., Ikeda Y., et al. Serum paraoxonase and arylesterase activities in hemodialysis patients. J. Atheroscler. Thromb. 7 (2000) 152-158
38. Brattström L., Lindgren A., Israelsson B., et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and risk factors. Eur. J. Clin. Invest. 22 (1992) 214-221
39. Malinow M.R., Levenson J., Giral P., et al. Role of blood pressure, uric acid, and hemorhelogical parameters on plasma homocysteine concentration. Atherosclerosis 114 (1995) 175-183
40. Boers G.H. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin. Thromb. Hemost. 26 (2000) 291-295
41. Kerkeni M., Addad F., Chauffert M., et al. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann. Clin. Biochem. 43 (2006) 200-206
42. Brattström L., and Wilcken D.E. Homocysteine and cardiovascular disease: cause or effect?. Am. J. Clin. Nutr. 72 (2000) 315-323
43. Guttormsen A.B., Ueland P.M., Svarstad E., and Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int. 52 (1997) 495-502
44. Blacher J., Demuth K., Guerin A.P., Safar M.E., Moatti N., and London G.M. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 535-541
45. Bostom A.G., and Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 52 (1997) 10-20
46. Perna A.F., Ingrosso D., Castaldo P., De Santo N.G., Galletti P., and Zappia V. Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Miner. Electrolyte Metab. 25 (1999) 95-99
47. Yi F., and Li P.L. Mechanisms of homocysteine induced glomerular injury and sclerosis. Am. J. Nephrol. 28 (2008) 264-524
48. Shastry S., Ingram A.J., Scholey J.W., and James L.R. Homocysteine induces mesangial apoptosis via activation of p38-mitogen-activated protein kinase. Kidney Int. 71 (2007) 304-311
49. Lacinski M., Skorupski W., Cieslinski A., Sokolowska J., Trzeciak W.H., and Jakubowski H. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell. Mol. Biol. 50 (2004) 885-893
50. Perna A.F., Satta E., Acanfora F., Lombardi C., Ingrosso D., and De Santo N.G. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int. 69 (2006) 869-876
51. Wlodek P.J., Smolenski O.B., Chwatko G., et al. Disruption of thiol homeostasis in plasma of terminal renal failure patients. Clin. Chem. Acta 366 (2006) 137-145
52. Kumagai H., Katoh S., Hirosawa K., Kimura M., Hishida A., and Ikegaya N. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kdney Int. 62 (2002) 1219-1228
53. Ossani G.P., Fischer P.A., Caram S.G., Dominguez G.N., Monserrat A.J., and Masnatta L.D. Mild hyperhomocysteinemia promotes renal hemodynamic dysfunction without histopathologic changes in adult rats. Kidney Int. 66 (2004) 1866-1872
54. O'Riordan E., Mendelev N., Patschan S., et al. Chronic NOS inhibition actuates endothelial mesenchymal transformation. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) 285-294
55. Fisher P.A., Dominguez G.N., Cunberti L.A., et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved?. J. Am. Soc. Nephrol. 14 (2003) 653-660
56. Stranger O., and Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin. Chem. Lab. Med. 41 (2003) 1444-1454
57. Kassab S., Garadah T., Abu-Hijleh M., et al. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats. J. Renin. Angiotensin Aldosterone Syst. 7 (2006) 206-211
58. Minuz P., Patrignani P., Gaino S., et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106 (2002) 2800-2805
59. Singh A.P., Singh M., and Balakumar P. Effect of mast cell stabilizers in hyperhomocysteinemia induced cardiac hypertrophy in rats. J. Cardiovasc. Pharmacol. 51 (2008) 596-604
60. Marsillach J., Martinez-Vea A., Marcas L., et al. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin. Exp. Pharmacol. Physiol. 34 (2007) 347-349
61. Joyeux-Faure M. Cellular protection by erythropoietin: new therapeutic implications?. JPET 323 (2007) 759-762